Review Article Abstract Introduction Retatrutide for Treatment of Obesity Retatrutide for Treatment of Type 2 Diabetes Effects of Retatrutide on Cardiovascular Risk Factors Safety of Retatrutide Effect of Retatrutide on Heart Rate Advantages of Retatrutide Limitations of Retatrutide Conclusions and Current Needs References Retatrutide for Treatment of Type 2 Diabetes In another phase 2 trial in the USA, retatrutide was evaluated for treatment of type 2 diabetes in comparison with subcutaneous dulaglutide (1.5mg/weekly) and placebo (Table 1) [4]
REDEFINE program results: - REDEFINE 1: 22.7% mean weight loss at 68 weeks
The evidence, however, does not strongly support this approach
Better glucose handling reduces the blood sugar swings that trigger hunger and cravings
Eli Lilly has signalled intent to file with the FDA in the United States and the EMA in Europe after the TRIUMPH-1, 2, and 3 readouts
Recently, a phase II multicentre, double-blind, randomized controlled trial including 338 adults with obesity were administered retatrutide (1, 2 mg starting dose increased to 4, 2 mg starting dose increased to 8, 2 mg starting dose increased to 12 mg) compared to placebo over 48 weeks [64]
)
